Although CCA is not usually a hypervascular tumor, regorafenib is still considered to be a potential therapeutic agent against this disease since several molecular alterations, including the disruption of the MAPK pathway and the activation of Ras and BRAF mutations, have been described in CCA. This evidence concerns the gene BRAF and cholangiocarcinoma.